

VEOLIA DELIVERS ENHANCED WASTEWATER TREATMENT FOR GLOBAL PHARMACEUTICAL INGREDIENT MANUFACTURER

CASE STUDY | Pharma, API manufacturer



| The client's needs

A major European pharmaceutical ingredient manufacturer has partnered with Veolia to enhance the wastewater treatment process at one of its sites in France. The manufacturer of active pharmaceutical ingredients (API), which has sites across Europe and serves a global customer base, sought to improve the performance of its onsite wastewater treatment with additional steps to ensure compliance with environmental regulations.


The API manufacturer required a quaternary treatment process to be implemented to complement and enhance the performance of its existing wastewater treatment plant. In particular, the client needed to achieve tighter controls on hard Chemical Oxygen Demand (COD), the organic and inorganic matter that is not easily biodegradable or simple to remove by conventional biological treatment methods. Also, due to the nature of the production, the effluent contained active ingredients that in wastewater are classified as micropollutants and therefore needed to be removed to comply with discharge standards.

| The solution

Following previous projects with the client, Veolia was contacted to provide a solution. The Veolia team carried out an assessment of the current wastewater characteristics and existing system performance to gain a full understanding of the technical requirements. From this, a combination of its Ozonia ozone generator, AnoxKaldnes™ Moving Bed Biofilm Reactor (MBBR), and Hydrotech™ disc filter was recommended and accepted by the client. The additional treatment process designed and installed by Veolia has a treatment capacity of 250 cubic metres per hour (m³/h) with the possibility of future expansion.

“With decades of experience in the industrial and pharmaceutical sectors, we are ideally placed to help clients achieve the water treatment performance required to meet even the strictest of modern discharge standards. Our diverse portfolio of water treatment solutions and technical expertise meant we were able to deliver the optimum solution to meet all the client's requirements.”

Etienne Fiquet, Market Development Manager at Veolia Europe



France


| The client

- European based, global supplier of active pharmaceutical ingredients (API).
- Six production sites across Europe.
- One of its French sites required wastewater treatment upgrades.

Key Figures

250 m³/h
Treatment Capacity

How the installation works




| Results

Veolia delivered a robust and reliable treatment solution to meet the client's needs with guarantees on the performance of the system. The enhancement of the treatment process has helped to protect the natural environment, ensure regulatory compliance and provide peace of mind for the client. In addition, Veolia also provided a three-year warranty on the new plant.

| Performance

The key water treatment performance criteria achieved and guaranteed by Veolia:

- Treatment capacity: 250 m³/h
- Total COD: < 300 mg/L +/-10%
- Toxicity: < 1.11 equitox/m³
- Fipronil (micropollutant): < 0.034 mg/L
- MB45950 (micropollutant): < 0.036 mg/L
- Triticonazole (micropollutant): < 1.2 mg/L



Veolia | Water Tech
2 Dukes Meadow • Bourne End • SL8 5XF
Tel: 020 3567 7000
www.veoliawatertechnologies.co.uk/